GlaxoSmithKline PLC is to cut nearly a third of its consumer healthcare products in Russia as executives across the pharmaceutical industry grapple with an ethical dilemma over their response to the war in Ukraine.
While hundreds of businesses from auto makers to brewers have pulled back from Russia, drugmakers have mostly maintained sales in the country, saying they are duty-bound to supply sometimes vital medicines even as they condemn the war.
To Read the Full Story
